NSRX

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Aug 17, 11:45 AMNasus Pharma reports Q2 2026 non-GAAP EPS -$0.54 (-500% YoY)

Peers: MIRA AMRN SCLX TXMD CPHI CTOR RMTI SCYX BGM CPIX

Scroll to Statements

Index	-
Market Cap	43.33M
Enterprise Value	39.36M
Income	-3.35M
Sales	0.00M
Book/sh	0.32
Cash/sh	0.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Aug 13, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	11.74
P/C	10.83
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.77
Current Ratio	8.77
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.33
EPS next Y	-1.14
EPS next Q	-0.12
EPS this Y	-58.90%
EPS next Y	1.72%
EPS next 5Y	11.27%
EPS past 3/5Y	-49.37% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-358.03%
Sales Q/Q	-
Earnings	Aug 17 BMO
EPS/Sales Surpr.	- -

Insider Own	66.91%
Insider Trans	0.31%
Inst Own	18.36%
Inst Trans	31.91%
ROA	-153.55%
ROE	-278.36%
ROIC	-90.35%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.74%
SMA50	15.55%
SMA200	-20.30%
Trades

Shs Outstand	11.71M
Shs Float	3.88M
Short Float	4.13%
Short Ratio	6.02
Short Interest	0.16M
52W High	9.99 -62.96%
52W Low	1.98 86.87%
Volatility	9.09% 8.33%
ATR (14)	0.29
RSI (14)	64.10
Beta	4.14
Rel Volume	0.63
Avg Volume	26.59K
Volume	14,251

Perf Week	11.78%
Perf Month	22.92%
Perf Quarter	34.55%
Perf Half Y	-37.92%
Perf YTD	-59.56%
Perf Year	-56.93%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	19.67
Prev Close	3.70
Price	3.70
Change %	0.00%

Aug-17-26 08:14AM	Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-26 07:30AM	Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth (GlobeNewswire)
Jun-22-26 08:00AM	Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum (GlobeNewswire)
Jun-09-26 08:00AM	Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) (GlobeNewswire)
Jun-01-26 08:00AM	Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis (GlobeNewswire)
09:14AM	Loading…
May-01-26 09:14AM	Nasus Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-26 09:00AM	Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update (GlobeNewswire) +10.84%
Mar-16-26 07:30AM	Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold (GlobeNewswire) -38.00%
Mar-09-26 08:30AM	Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study (GlobeNewswire) -15.43%
08:00AM	Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum (GlobeNewswire)
Feb-20-26 08:00AM	Nasus Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +18.00%
Feb-17-26 08:00AM	Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 (GlobeNewswire)
Feb-13-26 08:00AM	Nasus Pharma Announces Closing of $15.0 Million Private Placement (GlobeNewswire) +5.36%
Feb-10-26 11:03PM	Nasus Pharma Announces Pricing of $15.0 Million Private Placement (GlobeNewswire)
Jan-20-26 08:00AM	Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder (GlobeNewswire) -7.52%
08:00AM	Loading…
Dec-22-25 08:00AM	Nasus Pharma CEO Issues 2025 Letter to Shareholders (GlobeNewswire) -6.56%
Nov-20-25 08:15AM	Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer (GlobeNewswire)
Nov-18-25 08:00AM	Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed (GlobeNewswire)
Nov-06-25 08:00AM	Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder (GlobeNewswire)
Sep-02-25 08:00AM	Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 08:00AM	Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony (GlobeNewswire)
Aug-14-25 04:05PM	Nasus Pharma Announces Closing of Initial Public Offering (GlobeNewswire)
Aug-13-25 07:30AM	Nasus Pharma Announces Pricing of $10 Million Initial Public Offering (GlobeNewswire)

Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.

Co-Founder & Executive ChairmanMr. Ehud Moshe Gilboa MBA

M.D.Dr. Dalia Megiddo M.B.A.

CFO & Executive VPMr. Eyal Rubin M.B.A.

Chief Executive OfficerMr. Brendan P. O'Grady

Vice President of Administration & Human ResourcesMs. Yifat Bar

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Teleman Dan Benjamin	Chief Executive Officer	Jun 17 '26	Buy	3.10	6,550	20,305	163,541	Jun 22 07:12 AM
Teleman Dan Benjamin	Chief Executive Officer	Apr 22 '26	Buy	3.76	2,900	10,904	156,991	Apr 22 09:44 PM
Teleman Dan Benjamin	Chief Executive Officer	Mar 31 '26	Buy	2.04	15,000	30,600	21,246	Apr 01 07:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Nasus Pharma Ltd

Upgrade your Finviz experience